Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin

Mohan, Sowjanya; McDermott, Brian P.; Cunha, Burke A.

doi:10.1016/j.hrtlng.2004.07.009

Cited by 52 publications

(27 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, most patients have received daptomycin as salvage therapy following vancomycin failure [66,67]. Similarly, in the study reported by Fowler et al [62], most patients received vancomycin therapy for a mean of 2 days before starting either daptomycin treatment or standard therapy.…”

Section: Does Clinical Evidence Of Cross-resistance Between Vancomycimentioning

confidence: 95%

Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus

Boucher¹,

Sakoulas²

2007

Clinical Infectious Diseases

159

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus infections are becoming more frequent and less easily treated by means of currently recommended agents. Vancomycin has been associated with decreased susceptibility in staphylococci and with treatment failures. Daptomycin is rapidly bactericidal; a dosage of 4 mg/kg daily is approved for treatment of skin and soft-tissue infections, and a dosage of 6 mg/kg daily is approved for treatment of patients with S. aureus bacteremia and right-sided endocarditis. Findings of in vitro studies suggest a correlation between the minimum inhibitory concentrations of daptomycin and vancomycin. Clinical failure was associated with increasing minimum inhibitory concentrations in case reports and in a randomized study of persons with S. aureus bacteremia and endocarditis. Patients who did not respond to therapy had deep-seated infections that required but could not be or were not managed with adjunctive surgical therapy. No definitive resistance mechanism has been identified, although genetic mutations have been described. Clinically, prior vancomycin therapy has not been associated with failure of daptomycin therapy. Although clinical practitioners must monitor for daptomycin resistance, the available data support the use of daptomycin in the treatment of methicillin-resistant S. aureus bacteremia and endocarditis.

show abstract

Section: Does Clinical Evidence Of Cross-resistance Between Vancomycimentioning

confidence: 95%

Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus

Boucher¹,

Sakoulas²

2007

Clinical Infectious Diseases

159

View full text Add to dashboard Cite

show abstract

“…Daptomycin is a cyclic lipopeptide which has been recently approved by the U.S. Food and Drug Administration for the treatment of complicated skin and skin structure infections and has been evaluated for the treatment of several other infections, including successful studies of bacteremia and infectious endocarditis (14,21,26). Daptomycin has a unique mechanism of action with no cross-resistance to glycopeptide (teicoplanin and vancomycin)-resistant strains.…”

mentioning

confidence: 99%

Daptomycin Bactericidal Activity and Correlation between Disk and Broth Microdilution Method Results in Testing of Staphylococcus aureus Strains with Decreased Susceptibility to Vancomycin

Sader

Fritsche²,

Jones

2006

Antimicrob Agents Chemother

View full text Add to dashboard Cite

strains) and 102 wild-type methicillin-resistant S. aureus (MRSA-WT) strains were tested by reference/ standardized broth microdilution and disk diffusion methods, as well as by Etest (AB BIODISK, Solna, Sweden), against daptomycin and vancomycin. The lowest concentration of antimicrobial agent that killed >99.9% of the initial inoculum was defined as the minimum bactericidal concentration (MBC) endpoint, and time-kill curves were performed in selected strains to further evaluate bactericidal activity. All MRSA-WT and hVISA strains were inhibited by <1 g/ml of daptomycin, while the VISA strains showed slightly higher daptomycin MICs (range, 0.5 to 4 g/ml). All daptomycin MBC results were at the MIC or twofold higher. In contrast, 14.7% of MRSA-WT, 69.3% of hVISA, and all VISA strains showed a vancomycin MBC/MIC ratio of >32 or an MBC of >16 g/ml (tolerant). The correlation coefficients between broth microdilution and disk diffusion method results were low for daptomycin (0.07) and vancomycin (0.11). Eight (3.8%) strains (all hVISA or VISA) were "nonsusceptible" to daptomycin by broth microdilution methods but susceptible by the disk diffusion method. For vancomycin, 35 (16.9%) strains were nonsusceptible by broth microdilution methods but susceptible by disk diffusion methods. In conclusion, daptomycin was highly bactericidal against S. aureus strains, and its bactericidal activity was not affected by decreased susceptibility to vancomycin. In contrast, many (one in seven) contemporary MRSA-WT, the majority of hVISA, and all VISA strains showed vancomycin MBC/MIC ratios consistent with tolerance, a predictor of poor clinical response. Disk diffusion tests generally failed to detect strains categorized as nonsusceptible to daptomycin or vancomycin by the reference broth microdilution method or Etest, and reassessment of breakpoints should be immediately attempted for MIC methods suggested as the test of choice.

show abstract

“…Therefore, VAC technique can be accomplished safely The treatment of deep sternal wound infection has undergone several changes in the last 30 years. In our earlier experience, we adopted an aggressive treatment protocol, emphasizing timely debridement to prevent the infection spreading within the mediastinal space, allowing better clinical results than the previous conservative approach (13)(14)(15) . In 2006, we reported a comparative analysis of 19 patients operated between 1999 and 2006, and another 22 patients who underwent surgeries between 2006 and 2010, developing DSWI.…”

Section: Discussionmentioning

confidence: 99%

Role of Negative-Pressure Wound Therapy in Deep Sternal Wound Infection After Open Heart Surgery

Aydın¹,

Başel²,

Kara³

et al. 2013

Kosuyolu Kalp Derg

View full text Add to dashboard Cite

show abstract

Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin

Cited by 52 publications

References 7 publications

Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus

Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus

Daptomycin Bactericidal Activity and Correlation between Disk and Broth Microdilution Method Results in Testing of Staphylococcus aureus Strains with Decreased Susceptibility to Vancomycin

Role of Negative-Pressure Wound Therapy in Deep Sternal Wound Infection After Open Heart Surgery

Contact Info

Product

Resources

About